Stockreport

Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones

Erasca, Inc.  (ERAS) 
PDF Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharma [Read more]